Idorsia Pharmaceuticals Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Idorsia Pharmaceuticals Ltd
The Swiss biotech will be hoping that the improved daytime functioning seen with daridorexant in trials will allow the drug to complete in the DORA class led by Merck & Co's Belsomra and Eisai's Dayvigo.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
The Swiss biotech says that a late-stage trial of the dual orexin receptor antagonist daridorexant is the first study to demonstrate an insomnia product that can improve how the patient feels during the day, as well as aiding sleep at night.
- Drug Discovery Tools